Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCAR-T2C in Relapsed/Refractory CD4+ T Lymphocyte Tumor
NCT04219319Phase 1Terminated
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Dec 2021
- Primary completion
- Jul 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LB1901 in T-cell non-Hodgkin lymphoma and t-cell acute lymphoblastic leukemia (T-ALL), sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Dose Limiting Toxicity at 30 days, Adverse Events at 90 days and 2 more. Started Dec 2021; status: terminated.
02
Drugs
LB1901
03
Conditions
T-cell non-Hodgkin lymphomat-cell acute lymphoblastic leukemia (T-ALL)
Beyond the preview
Go deeper on NCT04219319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04219319.